Italian registry checks if patients stay on cholesterol drug

NCT ID NCT07375225

Recruiting now Disease control Sponsor: Federico II University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This registry is tracking 1,500 Italian patients who are prescribed alirocumab 300 mg injections for high cholesterol. Researchers want to see how consistently patients take the medication and how well it lowers their cholesterol in real-life settings. The study also monitors side effects. It is purely observational and does not test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Alirocumab (Praluent) injection
What this could lead to: If successful, this study could show that alirocumab works well in everyday use, helping doctors manage high cholesterol more effectively.
What could go wrong: This is an observational registry, not a controlled trial, so results may be influenced by patient selection or other factors. It does not test a new drug or cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERCHOLESTEROLAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypercholesterolemia hypercholesterolemia, familial, 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERCHOLESTEROLAEMIA

Contacts and locations

Locations

Federico II University of Naples, Department of Advanced Biomedical Sciences
RECRUITING

Naples, Napoli, 80131, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.